Market Cap 543.05M
Revenue (ttm) 263.40M
Net Income (ttm) -198.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -75.51%
Debt to Equity Ratio 0.00
Volume 2,147,600
Avg Vol 2,685,774
Day's Range N/A - N/A
Shares Out 72.99M
Stochastic %K 29%
Beta 2.19
Analysts Strong Sell
Price Target $14.03

Company Profile

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders f...

Industry: Biotechnology
Sector: Healthcare
Phone: 203 535 1456
Address:
5 Science Park, 395 Winchester Avenue, New Haven, United States
TradingTomo
TradingTomo Jun. 20 at 8:47 PM
yall check out $ARVN after we secure these profits from RDGL
0 · Reply
buyandsold
buyandsold Jun. 18 at 4:33 PM
$ARVN i own too much and look forward to the day I can say it was not enough
3 · Reply
LongRKvis
LongRKvis Jun. 17 at 7:44 PM
$ARVN Opportunity.
0 · Reply
BioRich
BioRich Jun. 17 at 6:32 PM
$ARVN Excellent news for Arvinas. Definitley a winner here. I know it's taken its hits but keeps plugged along. The science and pipeline are excellent. Extremely cheap at these Share Prices. Thanks @DonCorleone77 for sharing the write-up. Follow/Subscribe for more suggestions and perspective. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital $XBI $QQQ $IBB
1 · Reply
G101SPM
G101SPM Jun. 17 at 10:52 AM
$ARVN $7.75 ask. BUY/NEW LONG POSITION carries SPM 87.94 tag to $12.00 in midterm.
0 · Reply
QuantumToZERO
QuantumToZERO Jun. 14 at 10:08 PM
$ARVN decent
1 · Reply
NewGuyHere94
NewGuyHere94 Jun. 13 at 9:08 PM
$ARVN good news today, where do you think we end up next week?
1 · Reply
DonCorleone77
DonCorleone77 Jun. 13 at 11:08 AM
$ARVN Arvinas presents preclinical data from studies of ARV-393 Arvinas presented data from preclinical studies of ARV-393, the company's investigational PROteolysis TArgeting Chimera B-cell lymphoma 6 protein degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type and PDX models of transformed follicular lymphoma. In combination with oral small molecule inhibitors, ARV-393 demonstrated enhanced antitumor activity, including tumor regressions, in cell line-derived xenograft models of high-grade B-cell lymphoma and aggressive diffuse large B-cell lymphoma. The results from these preclinical studies were shared at the European Hematology Association 2025 Congress in Milan, Italy. Key findings from the preclinical studies included: Single-agent ARV-393 significantly reduced tumor burden in peripheral blood, bone marrow and spleen in a systemic PDX model of nTFHL-AI derived from a patient who relapsed post chemotherapy. This is potentially the first preclinical evidence of anti-tumor activity with an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model. ARV-393 monotherapy treatment resulted in robust tumor growth inhibition in two PDX models of tFL. ARV-393 in combination with 5 classes of SMIs targeting potentially cooperative oncogenic drivers demonstrated increased TGI in CDX models of HGBCL and aggressive DLBCL compared with the respective monotherapy treatments. Tumor regressions were observed when ARV-393 was combined with tazemetostat, palbociclib, acalabrutinib, or venetoclax. RNA sequencing studies carried out to further characterize downstream mechanism of action suggested that ARV-393 inhibits tumor cell cycle progression and promotes differentiation, driving antitumor activity and broad combinability in preclinical models.
2 · Reply
TraderJoe65
TraderJoe65 Jun. 12 at 6:26 PM
$ARVN FDA approved $URGN just now after the advisory panel voted against it last month. These biotechs are coming back with new energy.
0 · Reply
NewGuyHere94
NewGuyHere94 Jun. 12 at 12:44 PM
$ARVN reloading time 📈
0 · Reply
Latest News on ARVN
Arvinas to Present at Jefferies Global Healthcare Conference

May 30, 2025, 7:00 AM EDT - 24 days ago

Arvinas to Present at Jefferies Global Healthcare Conference


Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript

May 1, 2025, 9:40 PM EDT - 7 weeks ago

Arvinas, Inc. (ARVN) Q1 2025 Earnings Call Transcript


Top 3 Health Care Stocks That Are Set To Fly This Month

Mar 26, 2025, 7:06 AM EDT - 3 months ago

Top 3 Health Care Stocks That Are Set To Fly This Month

IOVA SLP


TradingTomo
TradingTomo Jun. 20 at 8:47 PM
yall check out $ARVN after we secure these profits from RDGL
0 · Reply
buyandsold
buyandsold Jun. 18 at 4:33 PM
$ARVN i own too much and look forward to the day I can say it was not enough
3 · Reply
LongRKvis
LongRKvis Jun. 17 at 7:44 PM
$ARVN Opportunity.
0 · Reply
BioRich
BioRich Jun. 17 at 6:32 PM
$ARVN Excellent news for Arvinas. Definitley a winner here. I know it's taken its hits but keeps plugged along. The science and pipeline are excellent. Extremely cheap at these Share Prices. Thanks @DonCorleone77 for sharing the write-up. Follow/Subscribe for more suggestions and perspective. That's how we find these gems and learn. Let's make some money. Cheers! ~BioRich Capital $XBI $QQQ $IBB
1 · Reply
G101SPM
G101SPM Jun. 17 at 10:52 AM
$ARVN $7.75 ask. BUY/NEW LONG POSITION carries SPM 87.94 tag to $12.00 in midterm.
0 · Reply
QuantumToZERO
QuantumToZERO Jun. 14 at 10:08 PM
$ARVN decent
1 · Reply
NewGuyHere94
NewGuyHere94 Jun. 13 at 9:08 PM
$ARVN good news today, where do you think we end up next week?
1 · Reply
DonCorleone77
DonCorleone77 Jun. 13 at 11:08 AM
$ARVN Arvinas presents preclinical data from studies of ARV-393 Arvinas presented data from preclinical studies of ARV-393, the company's investigational PROteolysis TArgeting Chimera B-cell lymphoma 6 protein degrader. BCL6 is a transcriptional repressor protein and a known driver of B-cell lymphomas. ARV-393 demonstrated significant single-agent activity in a patient derived xenograft model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type and PDX models of transformed follicular lymphoma. In combination with oral small molecule inhibitors, ARV-393 demonstrated enhanced antitumor activity, including tumor regressions, in cell line-derived xenograft models of high-grade B-cell lymphoma and aggressive diffuse large B-cell lymphoma. The results from these preclinical studies were shared at the European Hematology Association 2025 Congress in Milan, Italy. Key findings from the preclinical studies included: Single-agent ARV-393 significantly reduced tumor burden in peripheral blood, bone marrow and spleen in a systemic PDX model of nTFHL-AI derived from a patient who relapsed post chemotherapy. This is potentially the first preclinical evidence of anti-tumor activity with an efficacious BCL6-targeted small-molecule degrader in a human nTFHL-AI model. ARV-393 monotherapy treatment resulted in robust tumor growth inhibition in two PDX models of tFL. ARV-393 in combination with 5 classes of SMIs targeting potentially cooperative oncogenic drivers demonstrated increased TGI in CDX models of HGBCL and aggressive DLBCL compared with the respective monotherapy treatments. Tumor regressions were observed when ARV-393 was combined with tazemetostat, palbociclib, acalabrutinib, or venetoclax. RNA sequencing studies carried out to further characterize downstream mechanism of action suggested that ARV-393 inhibits tumor cell cycle progression and promotes differentiation, driving antitumor activity and broad combinability in preclinical models.
2 · Reply
TraderJoe65
TraderJoe65 Jun. 12 at 6:26 PM
$ARVN FDA approved $URGN just now after the advisory panel voted against it last month. These biotechs are coming back with new energy.
0 · Reply
NewGuyHere94
NewGuyHere94 Jun. 12 at 12:44 PM
$ARVN reloading time 📈
0 · Reply
jpenguin
jpenguin Jun. 11 at 7:04 PM
2 · Reply
360sage
360sage Jun. 11 at 5:29 PM
$ARVN ARVN currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on four factors related to earnings estimates.
0 · Reply
jpenguin
jpenguin Jun. 11 at 2:55 PM
$ARVN we need a close above $8 today to continue the bullish trend
1 · Reply
Sarah_0032
Sarah_0032 Jun. 11 at 9:22 AM
$ARVN https://www.zacks.com/stock/news/2479570/does-arvinas-arvn-have-the-potential-to-rally-94-93-as-wall-street-analysts-expect?cid=CS-STOCKTWITS-HL-tale_of_the_tape|consensus_price_target-2479570&adid=SYND_STOCKTWITS_HEADLINE_TALEOFTHETAPE_551_2479570
0 · Reply
360sage
360sage Jun. 10 at 11:27 PM
$ARVN After hours action seem to point to strong, continued upward trend.
0 · Reply
Winning_calls
Winning_calls Jun. 10 at 2:21 PM
$ARVN 🤔🤔🤔
0 · Reply
jpenguin
jpenguin Jun. 10 at 12:03 PM
$ARVN $8 break today?? 90% we breakthrough
0 · Reply
Stockboi_
Stockboi_ Jun. 9 at 7:58 PM
$ARVN raise the ceiling
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 7:40 PM
$ARVN 😉😉😉enjoying this members!
0 · Reply
Stockboi_
Stockboi_ Jun. 9 at 5:54 PM
$ARVN I added back above 7.50. Clear skies to 8.40s
0 · Reply
Winning_calls
Winning_calls Jun. 9 at 5:29 PM
$ARVN 😉😉🤞
0 · Reply
Stockboi_
Stockboi_ Jun. 9 at 1:57 PM
$ARVN stopped out because I had a very tight stop. Either we break 750 and blastoff or I’ll be interested again under 715.
0 · Reply